ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Arsenic in Drinking Water and Prostate Cancer: A Population-Based Case-Control Study in Northern Chile.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Environmental Nonessential Element Exposure and Urologic Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEpidemiologic evidence demonstrates increased lung, bladder, and skin cancer risk among individuals exposed to arsenic in drinking water. Some studies report associations with prostate cancer, but data are limited. This study aimed to examine the association between arsenic in drinking water and prostate cancer in Northern Chile. With its wide range of exposure (<10-860 µg/L), large population, and accurate information on historic exposures, Northern Chile is the best place to investigate the human carcinogenic effects of arsenic.
methodsA case-control study conducted from 2015 to 2019 enrolled 343 prostate cancer cases and 337 age-matched controls among men ages ≥40 years. Cases were ascertained from cancer committees, hospitals, and medical facilities in the area. Controls were ascertained from the Chile Voter Registry, including >90% of adults ages >50 years. Information on lifetime arsenic exposure and potential confounders such as smoking, family history, and prostate cancer screening were collected.
resultsTwenty-three percent of participants were exposed to arsenic concentrations >800 µg/L in their lifetime (80× recommended thresholds). Cases and controls were demographically similar. After adjustment for age and smoking status, participants with the highest quartile of lifetime cumulative and average arsenic concentrations in drinking water each had 1.14 (95% confidence interval, 0.71-1.84) and 1.17 (95% confidence interval, 0.73-1.89) times the odds of prostate cancer compared with participants with the lowest quartile of exposure, respectively.
conclusionsArsenic exposure in drinking water, even at high levels, was not associated with increased risk of prostate cancer. IMPACT: Our findings suggest that arsenic is not a risk factor for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.